HIGHLIGHTS OF ACCOMPLISHMENTS

• Research, development and commercial launch of 3 new products for Corning Life Sciences; Synthemax™, Osteo Assay Surface, Ultra-Web®
• Founded RETT Corporation, wrote fundable SBIR grant and developed strategic business plan
• Industrialization of several technology platforms including Phage Display and Yeast Two-Hybrid.
• Managed several successful joint development collaborations including: Geron, Surmodics, Donaldson, and Human Genome Sciences
• 20 plus years of industrial research and development experience in a broad range of disciplines
  
  

STRENGTHS

• Passion for the start up phase of product and technology development and taking ideas from the bench to the boardroom
• Clearly communicates complex ideas to diverse audiences
• Partnership management style that creates and builds trust worthy, long standing, profitable business relationships

PROFESSIONAL EXPERIENCE

Development Cell Culture Manager, Corning Incorporated, Corning, NY (2005- 2010)

• Led a team of 18 biologists and material scientists; discovered and developed novel supports for mammalian cell culture. Launched 3 new products.
• Discovered a completely synthetic surface for the expansion and differentiation of human embryonic stem cells (Synthemax™, first in class). Performed product development for 3 different formats of the surface and transferred the process to manufacturing.   2010 product launch.   Projected sales of $90-150MM in 2012.
• Industrialized the UltraWeb® nanofiber coated surface for more “In vivo-like” cell culture. Collaboration with Donaldson and Surmodics.  Managed the cell biology support for manufacturing process development for 2 formats.  Product launch - 2007.  2008 sales - more than $150,000.
• Developed more than 6 product specific cell based applications for the Osteo Assay surface. Managed cell culture support for manufacturing process development for two formats of the surface. Product launch in 2010
• Presented product tutorials both internally and externally for the Synthemax™ and Osteo Assay surfaces to educate customers and the CLS sales force to drive new product sales.
• Advised the Advanced Cell Culture products team as they explored a number of solutions for the culture of primary human hepatocytes to be used in toxicology testing.

Independent Consultant, Xcellerex, LLC, Marlborough, MA (2004-2005)

• Led a team of 6 biologists and engineers in the industrialization of novel process development concepts including HTS methods to optimize mammalian cell line expression of biologics.
• Evaluated existing cell lines and developed a scheme for the creation of Supercell™ a high expression cell line for process development and manufacturing.

Director of Research, RETT Corporation, Bellingham, MA (2003-2004)

• Founding member of biotech start-up, established all research business objects for the business

• Initiated and developed a strategic business plan and investor’s package
• Wrote an SBIR grant to fund proof of concept research to develop a novel cell free solution for toxicity testing (ADME Tox).  Grant awarded.

Director of Research, Interomex Biopharmaceuticals, Vancouver, B.C. (2001-2003)

• Led a proteomics screening team of 13; scientists conducting primary and secondary protein and drug binding assays
• Automated a novel yeast two-hybrid screen for protein-protein interactions in lymphocytes.

Associate Director of Research, Dyax Corp., Cambridge, MA (2000-2001)
Senior Research Scientist, Dyax Corp., Cambridge,  MA (1995-2000)

• Responsible for the identification and development of affinity ligands for the purification of therapeutic drug targets and proteins. Project manager on more than 5 collaborations. As Associate Director led a team of 8 scientists using phage display to develop peptide and antibody based therapeutics in collaboration with Human Genome Sciences.
• Developed novel and patented screening methodologies to allow for phage display libraries to be effectively used on whole cell (mammalian) targets and against highly defined targets in complex systems.
• Discovered therapeutically active antibodies and peptides for B lymphocyte stimulating factor (BLyS), the regulation of hypertension, osteoporosis, and HIV/AIDS transmission.
• Developed and patented methods for the selection of affinity matured peptides with therapeutically relevant binding characteristics.

Senior Research Scientist, Ariad Pharmaceuticals, Cambridge, MA (1992-1995)

• Performed proof of concept experiments in the development of the ARGENTTM cell signaling regulation technology.